Odesa National Medical University, Odesa, Ukraine
DOI 10.32782/2226-2008-2023-1-2
Hepatitis B virus and hepatitis C virus are common causes of chronic hepatitis; from 5 to 10% of cases of HBV infection with or without co-infection with the hepatitis D virus, and in about 75% of cases of HCV infection turn into a chronic form.
The aim of the study is a comparative analysis of the frequency of detection of certain alleles of IL-4(rs2243250), TNFα (rs1800620) and IL-10(rs1800896) in patients with chronic hepatitis B and chronic hepatitis C.
The most pronounced differences in the studied groups were found in allelic polymorphism of TNFα (rs1800620). In patients with chronic hepatitis B the homozygous variant GG TNFα (rs1800620) prevailed – 85,37 %, and in patients with chronic hepatitis C this genotype was found only in 19,0 % of patients. Heterozygous variant GA TNFα (rs1800620) prevailed in patients with chronic hepatitis C (77,0 %), in patients with chronic hepatitis B it was observed only in 14,67 % of patients. A small number of patients with chronic hepatitis C (4,0%) had a homozygous variant of AA TNFα (rs1800620) (mutation), which was not found in patients with chronic hepatitis B. The difference between these indicators is statistically significant.
Significant differences in gene polymorphism TNFα (rs1800620) in patients with chronic hepatitis C and B showen the possibility of individual the genetic profile in chronic hepatitis. The absence of a significant difference in the frequency of IL-4 (rs2243250) and IL-10(rs1800896) genotypes may be a confirmation of the important role of these cytokines in the immunological segment of the patients’ genetic profile.
Key words: chronic hepatitis B, chronic hepatitis C, allelic polymorphism of cytokine genes.
REFERENCES
- Tsentr hromadskoho zdorovia MOZ Ukrainy. Zvit za rezultatamy likuvannia virusnykh hepatytiv u 2020 rotsi [Elektronnyi resurs] https://phc.org.ua/sites/default/files/users/user90/A4_zvit_gepatit1021_online_zamina.pdf
- EASL 2017. Clinical Practice Guidelines on the management of hepatitis B virus infection. European Association for the Study of the Liver. J Hepatol. 2017: 67(2); 370-398. doi: 10.1016/j.jhep.2017.03.021.
- European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. Hepatol. 2017; 66(1): 153–94. doi:10.1016/j.jhep.2016.09.001.
- Bruno S, Di Marco V, Iavarone [et al]. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J.Hepatol. 2016: 64(6); 1217-1223. doi: 10.1016/j.jhep.2016.01.034.
- Petta S, Craxì A. Current and future HCV therapy: do we still need other anti-HCV drugs. Liver Int. 2015: 1; 4-10. doi: 10.1111/liv.12714.
- Thibault PA, Huys A, Amador-Cañizares Y [et al].Regulation of hepatitis C virus genome replication by Xrn1 and microRNA – 122 binding to individual sites in the 5’ UTR. Journal virology. 2015: 89; 6294-6311. doi:10.1128/JVI.03631-14.
- Koumbi L, Karayiannis. The epigenetic control of hepatitis B virus modulates the outcome of infection. Front Microbiol. 2016; 6: 1491. doi:10.3389/fmicb.2015.01491.